Silence Therapeutics Plc ADR (NASDAQ:SLN)’s traded shares stood at 0.38 million during the last session, with the company’s beta value hitting 1.32. At the close of trading, the stock’s price was $2.57, to imply an increase of 17.35% or $0.38 in intraday trading. The SLN share’s 52-week high remains $24.38, putting it -848.64% down since that peak but still an impressive 23.35% since price per share fell to its 52-week low of $1.97. The company has a valuation of $121.36M, with an average of 0.35 million shares in intraday trading volume over the past 10 days and average of 293.33K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Silence Therapeutics Plc ADR (SLN), translating to a mean rating of 1.67. Of 4 analyst(s) looking at the stock, 0 analyst(s) give SLN a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.31.
Silence Therapeutics Plc ADR (NASDAQ:SLN) trade information
After registering a 17.35% upside in the last session, Silence Therapeutics Plc ADR (SLN) has traded red over the past five days. The 5-day price performance for the stock is -1.53%, and -36.70% over 30 days. With these gigs, the year-to-date price performance is -62.65%. Short interest in Silence Therapeutics Plc ADR (NASDAQ:SLN) saw shorts transact 1.41 million shares and set a 6.86 days time to cover.
The extremes give us $49 and $67 for target low and target high price respectively. As such, SLN has been trading -2507.0% off suggested target high and -1806.61% from its likely low.
Silence Therapeutics Plc ADR (SLN) estimates and forecasts
The rating firms project that company’s revenue will shrink -25.33% compared to the previous financial year.
Revenue forecast for the current quarter as set by 4 analysts is 3.58M. Meanwhile, for the current quarter, a total of 4 analyst(s) estimate revenue growth to 3.57M.Earnings reports from the last fiscal year show that sales brought in 12.41M and 598k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -71.13% before jumping 497.10% in the following quarter.
SLN Dividends
Silence Therapeutics Plc ADR has its next earnings report out in May. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Silence Therapeutics Plc ADR (NASDAQ:SLN)’s Major holders
Silence Therapeutics Plc ADR insiders hold 20.67% of total outstanding shares, with institutional holders owning 54.90% of the shares at 69.21% float percentage. In total, 54.90% institutions holds shares in the company, led by TCG CROSSOVER MANAGEMENT, LLC. As of 2024-06-30, the company held over 3.3 million shares (or 2.3503% of shares), all amounting to roughly $62.61 million.
The next major institution holding the largest number of shares is ARTAL GROUP S.A. with 2.78 million shares, or about 1.9825% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $52.81 million.
We also have MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund and iShares Trust-iShares Biotechnology ETF as the top two Mutual Funds with the largest holdings of the Silence Therapeutics Plc ADR (SLN) shares. Going by data provided on Dec 31, 2024 , MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund holds roughly 640.0 shares. This is just over 2.14% of the total shares, with a market valuation of $1.64 million. Data from the same date shows that the other fund manager holds a little less at 172.72, or 0.58% of the shares, all valued at about 0.44 million.
